keytruda merck - Search News

Merck, Keytruda and WSJ

Reuters on MSN · 3d

New version of Merck's Keytruda faces possible patent battle, WSJ reports

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

The Wall Street Journal on MSN · 3d

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Markets Insider · 4d

Merck’s Keytruda subject of brewing patent dispute with Halozyme, WSJ says

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in

Seeking Alpha on MSN · 4d

Merck set for patent battle with Halozyme over injectable Keytruda: WSJ

A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, and Merck (NYSE:MRK) over an injectable version of the New Jersey-based pharma giant’s cancer blockbuster,

Fierce Pharma2d

In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Merck’s Injectable Keytruda Plans Create Legal Dispute With Halozyme: WSJ

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

11don MSN

Merck expects cancer therapy Keytruda to be part of government price setting in 2026

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

Fierce Pharma10d

Merck expects oncology king Keytruda to face IRA 'price setting' process starting in 2026

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

10 Best-Selling Drugs of 2024 Rake in Billions Amid Exclusivity Threats

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

4d

Merck (MRK) Battling to Protect Key Cancer Drug as Patent Row Heats Up

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

Pharmalittle: We’re reading about lower Wegovy prices, a dispute over Merck’s Keytruda, and more

Novo Nordisk plans to offer its Wegovy weight loss drug at a reduced cost of $499 per month for cash-paying customers in the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results